Karyopharm Therapeutics (KPTI) Other Operating Expenses (2019 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Other Operating Expenses came in at $1.5 million in Q4 2025, up 11.5% YoY from $1.3 million in Q4 2024, and down 29.77% on a QoQ basis from $2.1 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Other Operating Expenses (2019 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Other Operating Expenses data on file, last reported at $1.5 million in Q4 2025.
- Quarterly Other Operating Expenses rose 11.5% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (down 0.97% YoY) and the FY2025 annual result came in at $5.9 million, down 0.97% from the prior year.
- Other Operating Expenses fell to $1.5 million in Q4 2025, from $2.1 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $2.1 million in Q3 2025 to a low of -$73.8 million in Q1 2021.
- A 5-year average of -$2.5 million and a median of $1.3 million in 2024 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2021 — Other Operating Expenses sank 9106.96% — and 2022, when it jumped 151.75%.
- Tracing KPTI's Other Operating Expenses over 5 years: stood at $742000.0 in 2021, then jumped by 151.75% to $1.9 million in 2022, then retreated by 20.45% to $1.5 million in 2023, then fell by 10.43% to $1.3 million in 2024, then rose by 11.5% to $1.5 million in 2025.
- The last three Other Operating Expenses figures came in at $1.5 million (Q4 2025), $2.1 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.09 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 1.49 Mn |
| Sep 30, 2023 | 911,000.00 |
| Jun 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.35 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 980,000.00 |
| Jun 30, 2022 | 939,000.00 |
| Mar 31, 2022 | 1.43 Mn |
| Dec 31, 2021 | 742,000.00 |
| Sep 30, 2021 | 589,000.00 |
| Jun 30, 2021 | 1.14 Mn |